50. Dermatomyositis Clinical trials / Disease details


Clinical trials : 182 Drugs : 229 - (DrugBank : 88) / Drug target genes : 48 - Drug target pathways : 147

  
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04999020
(ClinicalTrials.gov)
December 2, 20214/8/2021Ravulizumab Versus Placebo in Adult Participants With DermatomyositisA Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With DermatomyositisDermatomyositisDrug: Ravulizumab;Drug: PlaceboAlexion PharmaceuticalsNULLRecruiting18 YearsN/AAll180Phase 2/Phase 3United States;France;Germany;Italy;Korea, Republic of;Spain
2EUCTR2021-001200-15-DE
(EUCTR)
05/10/202115/06/2021Ravulizumab versus Placebo in Adult Participants with Dermatomyositis.A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Dermatomyositis. - Ravulizumab versus Placebo in Adult Participants with Dermatomyositis. Dermatomyositis
MedDRA version: 20.0;Level: PT;Classification code 10012503;Term: Dermatomyositis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: Ultomiris
Product Name: Ravulizumab
Product Code: ALXN1210
INN or Proposed INN: RAVULIZUMAB
Other descriptive name: ALXN1210
Trade Name: Ultomiris
Product Name: Ravulizumab
Product Code: ALXN1210
INN or Proposed INN: RAVULIZUMAB
Other descriptive name: ALXN1210
Alexion Pharmaceuticals, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
180Phase 2;Phase 3France;United States;Spain;Germany;United Kingdom;Italy;Japan;Korea, Republic of
3EUCTR2021-001200-15-ES
(EUCTR)
27/09/202116/09/2021Ravulizumab versus Placebo in Adult Participants with Dermatomyositis.A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Dermatomyositis. - Ravulizumab versus Placebo in Adult Participants with Dermatomyositis. Dermatomyositis
MedDRA version: 20.0;Level: PT;Classification code 10012503;Term: Dermatomyositis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: Ultomiris
Product Name: Ravulizumab
Product Code: ALXN1210
INN or Proposed INN: RAVULIZUMAB
Other descriptive name: ALXN1210
Trade Name: Ultomiris
Product Name: Ravulizumab
Product Code: ALXN1210
INN or Proposed INN: RAVULIZUMAB
Other descriptive name: ALXN1210
Alexion Pharmaceuticals, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
180Phase 2;Phase 3France;United States;Spain;Germany;United Kingdom;Italy;Japan;Korea, Republic of
4EUCTR2021-001200-15-IT
(EUCTR)
16/08/202118/10/2021Ravulizumab versus Placebo in Adult Participants with Dermatomyositis.A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Dermatomyositis. - Ravulizumab versus Placebo in Adult Participants with Dermatomyositis. Dermatomyositis;Therapeutic area: Diseases [C] - Immune System Diseases [C20]Trade Name: Ultomiris
Product Name: Ravulizumab
Product Code: [ALXN1210]
INN or Proposed INN: RAVULIZUMAB
Other descriptive name: ALXN1210
Trade Name: Ultomiris
Product Name: Ravulizumab
Product Code: [ALXN1210]
INN or Proposed INN: RAVULIZUMAB
Other descriptive name: ALXN1210
Trade Name: Nimenrix
Product Name: Nimenrix
Product Code: [NA]
INN or Proposed INN: tetanus protein
Other descriptive name: tetanus protein
INN or Proposed INN: NEISSERIA MENINGITIDIS GROUP A POLYSACCHARIDE CONJUGATED WITH TETANUS TOXOID CARRIER PROTEIN
Other descriptive name: NEISSERIA MENINGITIDIS GROUP A POLYSACCHARIDE CONJUGATED WITH TETANUS TOXOID CARRIER PROTEIN
INN or Proposed INN: NEISSERIA MENINGITIDIS GROUP W-135 POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID CARRIER PROTEIN
Other descriptive name: NEISSERIA MENINGITIDIS GROUP W-135 POLYSACCHARIDE CONJUGATED TO TETA
ALEXION PHARMACEUTICALS INCORPORATEDNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
180Phase 2;Phase 3France;United States;Spain;Germany;United Kingdom;Japan;Italy;Korea, Republic of
5EUCTR2021-001200-15-FR
(EUCTR)
10/08/202128/06/2021Ravulizumab versus Placebo in Adult Participants with Dermatomyositis.A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Dermatomyositis. - Ravulizumab versus Placebo in Adult Participants with Dermatomyositis. Dermatomyositis
MedDRA version: 20.0;Level: PT;Classification code 10012503;Term: Dermatomyositis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: Ultomiris
Product Name: Ravulizumab
Product Code: ALXN1210
INN or Proposed INN: RAVULIZUMAB
Other descriptive name: ALXN1210
Trade Name: Ultomiris
Product Name: Ravulizumab
Product Code: ALXN1210
INN or Proposed INN: RAVULIZUMAB
Other descriptive name: ALXN1210
Alexion Pharmaceuticals, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
180Phase 2;Phase 3United States;France;Spain;Germany;United Kingdom;Italy;Japan;Korea, Republic of